Aysa Rezabakhsh
1* 
, Alireza Ala
2, Sepideh Hassanpour Khodaei
31 Rehabilitation and Physical Medicine Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran
2 Emergency Medicine Research Team, Tabriz University of Medical Sciences, Tabriz, Iran
3 Department of Dentistry, Eastern Mediterranean University Famagusta, North Cyprus, Mersin 10, Turkey
*Corresponding Author: Aysa Rezabakhsh, PhD of pharmacology, Aging research institute, Golghasht street, Tabriz University of Medical Sciences Tabriz, Iran, Tel:+98-4133352078, Fax:+98-4136581558 Email: aysapharma.rezabakhsh@gmail.com,, Email:
rezabakhsha@tbzmed.ac.ir
Abstract
Coronavirus disease 2019 (COVID-19), with high-transmission power, is spreading rapidly, and researchers are endeavoring to discover eligible medications for its efficacious prevention and treatment globally. According to the World Health Organization (WHO) reports, several multicenter clinical trials are launched to determine effective treatment protocols against COVID- 19-associated pneumonia. In this article, we aimed to discuss some critical issues concerning novel coronavirus.